• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

NASDAQ

Nasdaq grants Titan Medical 180-day extension to regain compliance

June 29, 2022 By Sean Whooley

Titan Medical (Nasdaq:TMDI) announced today that it received an additional 180 days to regain compliance with the Nasdaq market. According to a news release, the Listing Qualifications Staff of The Nasdaq Stock Market notified the company that it received 180 extra calendar days — running through Dec. 26, 2022 — to evidence compliance with the […]

Filed Under: Business/Financial News, Featured, News Well, Surgical, Surgical Robotics, Wall Street Beat Tagged With: NASDAQ, robot-assisted, Robotic Surgery, Titan Medical Inc.

Conformis could face Nasdaq delisting

January 4, 2022 By Sean Whooley

Conformis (NSDQ:CFMS) announced today that it is not in compliance with the minimum bid price requirement for continued Nasdaq listing. The company received a letter from Nasdaq on Dec. 31, 2021, notifying it that the closing bid price for its common stock had been below $1 for the previous 30 consecutive business days, meaning Conformis […]

Filed Under: Business/Financial News, Featured, Implants, News Well, Orthopedics, Wall Street Beat Tagged With: conformis, NASDAQ

Nasdaq halts trading of TransMedics stock with FDA set to review OCS Liver System

July 14, 2021 By Sean Whooley

TransMedics (NSDQ:TMDX) announced today that the Nasdaq market halted trading of the company’s common stock. Andover, Mass.-based TransMedics, which develops organ transplant transportation platforms, saw its common stock close down -5.3% at $31.69 yesterday. The company awaits the outcome of today’s meeting of the FDA’s Gastroenterology and Urology Devices Panel of the Medical Devices Advisory […]

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), Pre-Market Approval (PMA), Regulatory/Compliance, Transplants, Wall Street Beat Tagged With: FDA, FDA advisory panels, NASDAQ, transmedics

NeuroOne gains Nasdaq listing

May 26, 2021 By Sean Whooley

NeuroOne Medical Technologies (OTC:NMTC) announced that it was approved to uplist and begin trading on the Nasdaq market. Eden Prairie, Minn.-based NeuroOne expects trading to commence today at the open of the market, with the company trading under the “NMTC” ticker, according to a news release. The developer of surgical care options for patients suffering […]

Filed Under: Bioelectronic Medicine, Business/Financial News, Featured, Neurological, Neuromodulation/Neurostimulation, Pain Management, Wall Street Beat Tagged With: NASDAQ, neuroone

Second Sight facing Nasdaq delisting

October 5, 2020 By Sean Whooley

Second Sight Medical (NSDQ:EYES) announced that it received a letter from the Nasdaq market confirming that it may face delisting. The Sylmar, Calif.-based developer and manufacturer of implantable visual prosthetics for blind individuals received the letter confirming that its common stock had closed below the $1 per share minimum required for continued listing for 30 consecutive […]

Filed Under: Business/Financial News, Optical/Ophthalmic, Wall Street Beat Tagged With: NASDAQ, Second Sight

Acutus Medical launches IPO on Nasdaq

August 6, 2020 By Sean Whooley

Cardiac mapping technology developer Acutus Medical announced that it priced its initial public offering on the Nasdaq market. The Carlsbad, Calif.-based company is offering 8,823,529 shares of its common stock at $18 per share, with gross proceeds expected to come in at approximately $158.8 million. Acutus Medical’s shares are expected to begin trading today (Aug.6, […]

Filed Under: Business/Financial News, Cardiovascular, Catheters, Featured, Funding Roundup, Initial Public Offering (IPO), Vascular, Wall Street Beat Tagged With: Acutus Medical, NASDAQ

Hancock Jaffe Labs in danger of losing NASDAQ listing

March 27, 2020 By Sean Whooley

NASDAQ has warned Hancock Jaffe Laboratories (NSDQ:HJLI) that it is in danger of being delisted, but the company said in an SEC filing today that it intends to return to compliance. The warning, issued last week, said Hancock Jaffe did not have the minimum of $2.5 million in stockholders’ equity to merit its listing on the […]

Filed Under: Business/Financial News, Featured, Wall Street Beat Tagged With: hancockjaffelabs, NASDAQ

Pavmed back in NASDAQ compliance

January 13, 2020 By Nancy Crotti

Pavmed (NSDQ:PAVM) said today that it has received formal notice from NASDAQ that it has returned to compliance with the stock exchange’s listing rule after 10 consecutive days with a closing bid price of at least $1 per share. NASDAQ warned the company in November that it was in danger of delisting due to poor […]

Filed Under: Business/Financial News, Catheters, Featured, Surgical, Wall Street Beat Tagged With: NASDAQ, Pavmed

Pavmed threatened with stock exchange delisting

November 4, 2019 By Nancy Crotti

Pavmed (NSDQ:PAVM) is in danger of losing its listing on the NASDAQ exchange, according to a report filed with the Securities & Exchange Commission. In August last year, the FDA group reviewing Pavmed’s 510(k) application for its CarpX minimally invasive carpal tunnel release device asked the company to resubmit the application because the group hadn’t reached […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: FDA, NASDAQ, Pavmed, Securities & Exchange Commission (SEC)

Invuity closes $47.8m IPO

June 19, 2015 By Fink Densford

Invuity (NSDQ:IVTY) said it closed its initial public offering, raising approximately $47.8 million by offering 4.6 million shares at $12 per share. Leerink Partners, Piper Jaffray and Stifel were book-runners for the offering, with William Blair acting as co-manager, the company said. The IPO’s underwriters exercised a 600,000-share over-allotment, the San Francisco, Calif.-based surgical illumination device company […]

Filed Under: Business/Financial News, Initial Public Offering (IPO), Surgical Tagged With: Invuity, Laser/Light-based Devices, NASDAQ

UPDATE: Invuity prices IPO at $12 per share, under the range

June 12, 2015 By Fink Densford

Invuity yesterday priced its initial public offering at $12 a share, under the range the advanced surgical lighting maker set earlier in June, looking to raise $48 million. Invuity shares were set to begin trading today under the “IVTY” symbol on the NASDAQ exchange, the company said, but plans for opening have been delayed until […]

Filed Under: Business/Financial News, Initial Public Offering (IPO), Surgical Tagged With: Invuity, Laser/Light-based Devices, NASDAQ

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy